Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.
Coltelli L, Allegrini G, Orlandi P, Finale C, Fontana A, Masini LC, Scalese M, Arrighi G, Barletta MT, De Maio E, Banchi M, Fini E, Guidi P, Frenzilli G, Donati S, Giovannelli S, Tanganelli L, Salvadori B, Livi L, Meattini I, Pazzagli I, Di Lieto M, Pistelli M, Casadei V, Ferro A, Cupini S, Orlandi F, Francesca D, Lorenzini G, Barellini L, Falcone A, Cosimi A, Bocci G. Coltelli L, et al. Among authors: fini e. NPJ Breast Cancer. 2022 Mar 21;8(1):33. doi: 10.1038/s41523-022-00400-6. NPJ Breast Cancer. 2022. PMID: 35314692 Free PMC article.
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer.
Fornaro L, Musettini G, Orlandi P, Pecora I, Vivaldi C, Banchi M, Salani F, Fini E, Massa V, Catanese S, Cucchiara F, Lencioni M, Masi G, Vasile E, Bocci G. Fornaro L, et al. Among authors: fini e. Am J Cancer Res. 2022 Jul 15;12(7):3347-3356. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968330 Free PMC article.
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future.
Tuccori M, Convertino I, Ferraro S, Valdiserra G, Cappello E, Fini E, Focosi D. Tuccori M, et al. Among authors: fini e. Expert Opin Drug Discov. 2021 Dec;16(12):1403-1414. doi: 10.1080/17460441.2021.1960819. Epub 2021 Jul 30. Expert Opin Drug Discov. 2021. PMID: 34304682 Free PMC article. Review.
46 results